Nisa Investment Advisors LLC Boosts Stock Position in Boston Scientific Co. (NYSE:BSX)

Nisa Investment Advisors LLC increased its holdings in Boston Scientific Co. (NYSE:BSX) by 15.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 372,867 shares of the medical equipment provider’s stock after purchasing an additional 50,397 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Boston Scientific were worth $28,714,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of BSX. SVB Wealth LLC increased its stake in shares of Boston Scientific by 12.0% during the fourth quarter. SVB Wealth LLC now owns 14,051 shares of the medical equipment provider’s stock valued at $812,000 after buying an additional 1,503 shares during the period. Daiwa Securities Group Inc. increased its position in Boston Scientific by 5.2% during the 4th quarter. Daiwa Securities Group Inc. now owns 158,722 shares of the medical equipment provider’s stock valued at $9,176,000 after purchasing an additional 7,796 shares during the period. Twin Capital Management Inc. raised its holdings in Boston Scientific by 8.6% in the 4th quarter. Twin Capital Management Inc. now owns 22,996 shares of the medical equipment provider’s stock worth $1,329,000 after purchasing an additional 1,816 shares in the last quarter. Cambridge Trust Co. lifted its position in shares of Boston Scientific by 14.7% in the 4th quarter. Cambridge Trust Co. now owns 3,647 shares of the medical equipment provider’s stock worth $211,000 after purchasing an additional 467 shares during the period. Finally, AIA Group Ltd boosted its stake in shares of Boston Scientific by 86.4% during the 4th quarter. AIA Group Ltd now owns 22,317 shares of the medical equipment provider’s stock valued at $1,290,000 after purchasing an additional 10,346 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,011 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total transaction of $1,055,588.74. Following the completion of the sale, the executive vice president now directly owns 20,197 shares in the company, valued at approximately $1,521,641.98. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP Arthur C. Butcher sold 14,011 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $75.34, for a total value of $1,055,588.74. Following the transaction, the executive vice president now owns 20,197 shares of the company’s stock, valued at $1,521,641.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90. Following the sale, the executive vice president now directly owns 42,908 shares of the company’s stock, valued at $3,316,788.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,960 shares of company stock worth $2,638,984. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $0.45 during trading on Monday, reaching $78.70. 2,602,159 shares of the company traded hands, compared to its average volume of 6,202,487. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The firm has a 50 day simple moving average of $76.41 and a 200-day simple moving average of $72.01. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $79.43. The stock has a market capitalization of $115.46 billion, a PE ratio of 65.76, a P/E/G ratio of 2.49 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. The business had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.53 EPS. Equities research analysts anticipate that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research reports. Mizuho increased their price target on shares of Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, May 15th. Morgan Stanley raised their target price on Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. Wells Fargo & Company upped their price target on Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Robert W. Baird raised their price objective on Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Finally, TD Cowen increased their price target on shares of Boston Scientific from $77.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Two analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $84.76.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.